seeking biotech alpha April 2019 insight

Novartis AG (NVS)

Thermo Fisher Scientific Inc. (TMO)

Novartis AG (NVS)

Novartis AG 2019 Q1 - Results - Earnings Call Slides

Apr. 24, 2019 6:32 AM ET | About: Novartis AG (NVS)

Biogen Inc. (BIIB)

Thermo Fisher Scientific Inc. (TMO)

Novartis AG (NVS)

Biogen Inc. 2019 Q1 - Results - Earnings Call Slides

Apr. 24, 2019 7:10 AM ET | About: Biogen Inc. (BIIB)

Thermo Fisher Scientific Inc. (TMO)

Boston Scientific Corporation (BSX)

Thermo Fisher Scientific Inc. 2019 Q1 - Results - Earnings Call Slides

Apr. 24, 2019 9:49 AM ET | About: Thermo Fisher Scientific Inc. (TMO)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation 2019 Q1 - Results - Earnings Call Slides

Apr. 24, 2019 9:50 AM ET|1 comment | About: Boston Scientific Corporation (BSX)

FARXIGA

Boston Scientific Corporation (BSX)

Trulicity® (dulaglutide)

FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

Mon June 10, 2019 8:00 AM|Business Wire|About: AZN

WILMINGTON, Del.--(BUSINESS WIRE)

FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58 June 10, 2019 08:00 AM Eastern Daylight Time WILMINGTON, Del.--(BUSINESS WIRE)

Trulicity® (dulaglutide)

Boston Scientific Corporation (BSX)

Trulicity® (dulaglutide)

Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes

Sun June 9, 2019 7:30 PM|PR Newswire|About: LLYPR Newswire

INDIANAPOLIS, June 9, 2019 /PRNewswire/

Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes REWIND data showed a consistent effect in people with and without established cardiovascular disease NEWS PROVIDED BY Eli Lilly and Company Jun 09, 2019, 19:30 ET INDIANAPOLIS, June 9, 2019 /PRNewswire/

seeking biotech alpha April 2019 insight

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

Tue April 23, 2019 6:30 AM|GlobeNewswire|About: BCTXF, MRK

BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF)

BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston POSTED ON APRIL 23, 2019 BY FARRAH DEAN BERKELEY, Calif., and VANCOUVER, British Columbia, April 23, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF)

VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

Basel, 23 April 2019

Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy

Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.1 About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive.2
The VENTANA HER2 Dual ISH DNA Probe Cocktail assay3 aids in identifying breast and gastric cancer patients eligible for the targeted Roche drug Herceptin (trastuzumab), providing fast results with widely available laboratory instruments.

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways:

SPINRAZA™(nusinersen)

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen)

Mon April 22, 2019 7:00 AM|Canada Newswire|About: BIIB

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

Tue April 23, 2019 6:19 PM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., April 23, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) April 23, 2019 AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

LOTUS Edge™ Aortic Valve System

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

LOTUS Edge™ Aortic Valve System

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

Tue April 23, 2019 5:17 PM|PR Newswire|About: BSXPR Newswire

MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX)

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System Transcatheter Aortic Valve Replacement Technology for Patients with Severe Aortic Stenosis Designed to Minimize Paravalvular Leakage, Offer Controlled Delivery and Repositionability Post Deployment NEWS PROVIDED BY Boston Scientific Corporation Apr 23, 2019, 17:17 ET MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX)

Stryker Corporation (SYK)

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

LOTUS Edge™ Aortic Valve System

Stryker reports first quarter 2019 operating results

Tue April 23, 2019 4:05 PM|GlobeNewswire|About: SYK

Kalamazoo, Michigan, April 23, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2019:

First Quarter Highlights

Reported net sales increased 8.5% to $3.5 billion
Organic net sales increased 7.3%
Reported operating income margin of 15.0%

Stryker reports first quarter 2019 operating results 04/23/2019 Kalamazoo, Michigan, April 23, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2019:

seeking biotech alpha April 2019 insight

KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib)

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib)

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

Mon April 22, 2019 6:45 AM|Business Wire|About: MRK

https://www.keytruda.com/

https://www.inlyta.com/

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) Approval Based on Results of KEYNOTE-426, Where KEYTRUDA in Combination With Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib April 22, 2019 06:45 AM Eastern Daylight Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK)

Taltz® (ixekizumab)

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib)

Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

04/22/2019Download PDF

INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company(NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study

Taltz is a prescription medicine used to treat adults with active psoriatic arthritis. Taltz is also a treatment for adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Medtronic VenaSeal(TM) Closure System Demonstrates Durable and Consistent Outcomes at Five Years in Patients with Chronic Venous Disease

Wed April 17, 2019 5:00 AM|InPublic US|About: MDT

Medtronic VenaSeal(TM) Closure System Demonstrates Durable and Consistent Outcomes at Five Years in Patients with Chronic Venous Disease (GLOBE NEWSWIRE via COMTEX) --DUBLIN and LONDON - April 17, 2019 - Medtronic plc (NYSE:MDT)

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1

Basel, April 16, 2019 - AveXis, a Novartis company,

Zolgensma, previously knowns as AVXS-101, is the proprietary gene therapy candidate from AveXis designed to treat spinal muscular atrophy (SMA).

SKYRIZI™(risankizumab)

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Amgen Biotech Experience (ABE) program in Tampa, Florida

Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Thu April 18, 2019 10:04 AM|Canada Newswire|About: ABBV

Welcome to the AbbVie Care Program

Amgen Biotech Experience (ABE) program in Tampa, Florida

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Amgen Biotech Experience (ABE) program in Tampa, Florida

Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida

Wed April 17, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

TAMPA, Fla., April 17, 2019 /PRNewswire/ -- The Amgen (AMGN) Foundation, together with the University of South Florida (USF)

Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida Long-Established Science Education Program to Give Local Secondary School Students Hands-On Biotechnology Lab Experience NEWS PROVIDED BY Amgen Apr 17, 2019, 16:00 ET TAMPA, Fla., April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with the University of South Florida (USF),

seeking biotech alpha April 2019 insight

guselkumab (Tremfya(R))

timing of treatment and serum creatinine (SCr) at treatment start

brolucizumab (RTH258) for patients with wet AMD

MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis

Mon April 15, 2019 4:25 PM|Accesswire|About: JNJ, MOR

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 15, 2019 / MorphoSys AG (MPSYF) (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR)

MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis You are here HOMEMEDIA AND INVESTORSINVESTOR & MEDIA INFORMATIONMORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN... April 15, 2019 / 10:01 pm, CEST Planegg/Munich, Germany, April 15, 2019 MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis

brolucizumab (RTH258) for patients with wet AMD

timing of treatment and serum creatinine (SCr) at treatment start

brolucizumab (RTH258) for patients with wet AMD

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

Apr 15, 2019

By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries
Filing is based on Phase III data from the HAWK and HARRIER trials for brolucizumab
Novartis used a priority review voucher to expedite review of brolucizumab in the US and, if approved by FDA, anticipates launching by the end of 2019

Basel, April 15, 2019

timing of treatment and serum creatinine (SCr) at treatment start

Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)

Mon April 15, 2019 6:45 AM|PR Newswire|About: MNKPR Newswire

STAINES-UPON-THAMES, United Kingdom, April 15, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)

NEWS PROVIDED BY Mallinckrodt plc Apr 15, 2019, 06:45 ET SHARE THIS ARTICLE STAINES-UPON-THAMES, United Kingdom, April 15, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)

Wuxi Biologics (Cayman) In... (WXXWY)

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

timing of treatment and serum creatinine (SCr) at treatment start

WuXi Biologics teams up with I-Mab Bio for clinical programs

Apr. 16, 2019 8:23 AM ET|About: Wuxi Biologics (Cayman) In... (WXXWY)|By: Mamta Mayani, SA News Editor

www.wuxibiologics.com

www.i-mabbiopharma.com.

WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs 2019/04/16 SHANGHAI, April 16, 2019 — WuXi Biologics (“WuXi Bio”) (2269.HK)

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

Tue April 16, 2019 7:00 AM|Business Wire|About: GILD

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences Inc. (GILD) and insitro

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis April 16, 2019 07:00 AM Eastern Daylight Time FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD)

Fast Track Designation for CTX001

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Tue April 16, 2019 7:00 AM|GlobeNewswire|About: CRSP, VRTX

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX)

www.crisprtx.com

www.vrtx.com

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)

seeking biotech alpha April 2019 insight

ZERBAXA® (ceftolozane and tazobactam)

FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for w/ BALVERSA™ (erdafitinib)

ZERBAXA® (ceftolozane and tazobactam)

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK) Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019

Sat April 13, 2019 7:00 AM|Business Wire|About: MRK

https://www.merckconnect.com/zerbaxa/dosing-administration/

Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019 ASPECT-NP Clinical Trial Results Demonstrated Non-Inferiority of ZERBAXA to Meropenem for Treating Ventilated Nosocomial Pneumonia in Primary and Key Secondary Endpoints April 13, 2019 07:00 AM Eastern Daylight Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK

INVOKANA® (canagliflozin)

FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for w/ BALVERSA™ (erdafitinib)

ZERBAXA® (ceftolozane and tazobactam)

INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Melbourne, Australia, April 14, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson
Phase 3 CREDENCE Study

INVOKANA® is a prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who have known heart disease

FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for w/ BALVERSA™ (erdafitinib)

QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Fri April 12, 2019 3:23 PM|Business Wire|About: QGEN

Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ (erdafitinib), developed by Janssen

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN

QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ (erdafitinib), developed by Janssen April 12, 2019 03:23 PM Eastern Daylight Time GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE:QGEN;

Bristol-Myers Squibb C... (BMY)

FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for w/ BALVERSA™ (erdafitinib)

Bristol-Myers shareholders back Celgene takeover

Apr. 12, 2019 10:54 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition Transaction on Track to Close in Third Quarter of 2019 CATEGORY: CORPORATE/FINANCIAL NEWS FRIDAY, APRIL 12, 2019 10:48 AM EDT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (NASDAQ:CELG) at the Special Meeting of Stockholders.

Balversa (erdafitinib)

Bristol-Myers Squibb C... (BMY)

EVENITY™ (romosozumab-aqqg)

BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations

BALVERSA is the first FGFR kinase inhibitor to receive U.S. FDA approval
Simultaneous approval of companion diagnostic intended to identify a subset of patients most likely to benefit from BALVERSA, offering a personalized treatment approach

Horsham, PA, April, 12 – The Janssen Pharmaceutical Companies of Johnson & Johnson

EVENITY™ (romosozumab-aqqg)

Bristol-Myers Squibb C... (BMY)

EVENITY™ (romosozumab-aqqg)

EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Mon April 15, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (AMGN)

https://www.evenity.com/?gclid=Cj0KCQjw19DlBRCSARIsAOnfReiQqEpkS6ybUoydhqLdA9g0GEamce9OF2uu6koD6LSDUpAdb2LZm90aAq52EALw_wcB&gclsrc=aw.ds

EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

seeking biotech alpha April 2019 insight

Vemlidy® (tenofovir alafenamide 25mg, TAF)

MAVIRETTM (glecaprevir/pibrentasvir tablets)

Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019

Thu April 11, 2019 9:18 AM|Business Wire|About: GILD

– Data Demonstrate Role of Gilead HCV Medicines in Difficult–to-Treat Patient Populations and in Real-World Settings –

– Latest HBV Data Reinforce Role of Treatment with Vemlidy and Demonstrate Progress in Cure Research –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)

https://www.vemlidy.com/

https://www.epclusa.com/

April 11, 2019 Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019 – Data Demonstrate Role of Gilead HCV Medicines in Difficult–to-Treat Patient Populations and in Real-World Settings – – Latest HBV Data Reinforce Role of Treatment with Vemlidy and Demonstrate Progress in Cure Research – FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 11, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD)

MAVIRETTM (glecaprevir/pibrentasvir tablets)

AbbVie's MAVIRET™ now reimbursed in Quebec

Thu April 11, 2019 9:00 AM|Canada Newswire|About: ABBV

MAVIRET is now listed under the "Régie de l'assurance maladie du Québec" List of Medications.
MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1
MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease (CKD).

MONTREAL, April 11, 2019 /CNW/ - AbbVie (ABBV)

MAVIRET treats people with chronic (long-lasting) hepatitis C in adults. Hepatitis C is caused by an infection with the hepatitis C virus (HCV). ● There are 2 medicines in MAVIRET. They are called glecaprevir and pibrentasvir

Testosterone Gel 1.62% CIII

MAVIRETTM (glecaprevir/pibrentasvir tablets)

SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg

Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States

Thu April 11, 2019 10:00 AM|Business Wire|About: TEVA

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVVF) (NYSE and TASE: TEVA)

Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of AndroGel ®i (testosterone gel) 1.62% CIII in the U.S.

SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

High Proportion of Patients Achieve Undetectable Viral Loads after Rapidly Starting SYMTUZA®1

Miami, FL., April 11, 2019

SYMTUZA® is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who: have not received anti-HIV-1 medicines in the past, or when their healthcare provider determines that they meet certain requirements. HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

LibtayoTM (cemiplimab) for treatment of adult patients w/ metastatic/ locally advanced (CSCC)

SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg

LibtayoTM (cemiplimab) for treatment of adult patients w/ metastatic/ locally advanced (CSCC)

Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)

Thu April 11, 2019 2:43 PM|Canada Newswire|About: SNY

Source: Sanofi (SNY) (EURONEXT: SAN) (NYSE: SNY)

* CSCC is the second most common skin cancer in Canadai

TORONTO, April 11, 2019 /CNW Telbec/ - Sanofi Genzyme

https://www.melanomanetwork.ca/skincancer/

LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg

LibtayoTM (cemiplimab) for treatment of adult patients w/ metastatic/ locally advanced (CSCC)

Sat April 13, 2019 4:00 AM|Business Wire|About: PFE

Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data - - - The Biologics License Application is expected to be submitted to the U.S. FDA by the end of 2020, subject to the successful completion of Phase 3 studies April 13, 2019 04:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE)

seeking biotech alpha April 2019 insight

Veracyte, Inc. (VCYT)

Phase 2 Study of VK2809 in Patients w/ Non-Alcoholic Fatty Liver Disease & Elevated LDL-Cholesterol

Veracyte (VCYT) Presents At 18th Annual Needham Healthcare Conference - Slideshow

Apr. 10, 2019 12:17 PM ET | About: Veracyte, Inc. (VCYT)

PIPELINE We continue to push the boundaries of scientific innovation by leveraging our RNA sequencing and machine learning capabilities to expand our current offerings and – eventually – enable earlier disease detection. Key product-development initiatives include:

Phase 2 Study of VK2809 in Patients w/ Non-Alcoholic Fatty Liver Disease & Elevated LDL-Cholesterol

Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8%88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver Fat Content at 12 Weeks, Including all Patients Receiving 5 mg Daily DosesVK2809 was Safe and Well Tolerated at all Doses Studied; No SAEs Reported in Any Cohort

SAN DIEGO, April 11, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX)

Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH

myChoice® HRD CDx test.

Phase 2 Study of VK2809 in Patients w/ Non-Alcoholic Fatty Liver Disease & Elevated LDL-Cholesterol

Galectin Therapeutics, Inc. (GALT)

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

Tue April 9, 2019 7:05 AM|GlobeNewswire|About: MYGNGlobeNewswire

SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN)

myChoice® HRD CDx

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test myChoice HRD Is Intended to Identify Patients with Ovarian, Fallopian or Primary Peritoneal Cancer Who May Benefit from Treatment with Zejula SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN)

Galectin Therapeutics, Inc. (GALT)

farnesoid X receptor agonist cilofexor (GS-9764) & acetyl-CoA carboxylase inhibitor firsocostat (GS-

Galectin Therapeutics, Inc. (GALT)

Galectin Therapeutics (GALT) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference - Slideshow

Apr. 9, 2019 2:19 PM ET | About: Galectin Therapeutics, Inc. (GALT)

OUR PIPELINE

Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH

farnesoid X receptor agonist cilofexor (GS-9764) & acetyl-CoA carboxylase inhibitor firsocostat (GS-

Apr 11, 2019

Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH

OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters

REGENERATE data to be presented during the Opening Ceremony of EASL

NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT)

PIPELINE Novel compounds being developed for liver diseases

farnesoid X receptor agonist cilofexor (GS-9764) & acetyl-CoA carboxylase inhibitor firsocostat (GS-

Gilead's GS-9674/GS-0976 shows positive action in POC NASH study

Apr. 11, 2019 7:08 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor

April 11, 2019 Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019 -- New Proof-of-Concept Data for Combination of Investigational FXR Agonist Cilofexor and ACC Inhibitor Firsocostat in NASH -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 11, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD)

seeking biotech alpha April 2019 insight

CAB CTLA-4 antibody (BA3071). BA3071 is a novel, CTLA-4 inhibitor

Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

CAB CTLA-4 antibody (BA3071). BA3071 is a novel, CTLA-4 inhibitor

BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy

Tue April 9, 2019 6:05 AM|GlobeNewswire|About: BGNEGlobeNewswire

SAN DIEGO and BEIJING, China and CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- BioAtla ®, LLC

https://www.bioatla.com/news/

BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy Plan to pursue development as a monotherapy and in combination with BeiGene’s investigational anti-PD-1 antibody, tislelizumab SAN DIEGO and BEIJING, China and CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- BioAtla ®, LLC,

LYNPARZA® (olaparib)

Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

CAB CTLA-4 antibody (BA3071). BA3071 is a novel, CTLA-4 inhibitor

LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

Wed April 10, 2019 6:45 AM|Business Wire|About: MRK

AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 42 Percent Versus Chemotherapy in Phase 3 OlympiAD Trial

First PARP Inhibitor Approved in the EU for This Indication and Third EU Approval for LYNPARZA

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (MRK)

https://www.lynparzahcp.com/recurrent-ovarian-cancer/olaparib-efficacy/first-line-efficacy.html

Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer PUBLISHED 10 April 2019 10 April 2019 07:00 BST AstraZeneca and MSD’s Lynparza reduced the risk of disease progression or death by 42% vs. chemotherapy in Phase III OlympiAD trial First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada

Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

Wed April 10, 2019 9:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE)

Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration Apr 10, 2019 at 9:00 AM EDT PDF Version SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento")

EVENITY™ (romosozumab-aqqg)

Insulins Valyou Savings Program

Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Tue April 9, 2019 3:57 PM|PR Newswire|About: AMGN, UCBJY
EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2)
EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)

PR Newswire

THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB)

NEWS PROVIDED BY Amgen Apr 09, 2019, 15:57 ET FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2)

Geron Corporation (GERN)

Insulins Valyou Savings Program

Geron (GERN) Presents At 18th Annual Needham Healthcare Conference - Slideshow

Apr. 9, 2019 3:49 PM ET|8 comments | About: Geron Corporation (GERN)

Insulins Valyou Savings Program

Sanofi provides unprecedented access to its insulins for one set monthly price

Wed April 10, 2019 5:00 AM|PR Newswire|About: SNY
* Further expansion of the Insulins Valyou Savings Program - now people can pay $99 for up to 10 boxes of pens and/or 10 mL vials per month

PR Newswire

BRIDGEWATER, N.J., April 10, 2019 /PRNewswire/ -- Starting in June, Sanofi (SNY)

Insulins Valyou Savings Program

BRIDGEWATER, N.J., April 10, 2019 /PRNewswire/ NEWS PROVIDED BY Sanofi Apr 10, 2019, 05:00 ET Sanofi provides unprecedented access to its insulins for one set monthly price * Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program * Further expansion of the Insulins Valyou Savings Program - now people can pay $99 for up to 10 boxes of pens and/or 10 mL vials per month

seeking biotech alpha April 2019 insight

(NASDAQ:REGN) will collaborate with Alnylam Pharmaceuticals (NASDAQ:ALNY)

Systemic Gene Transfer w/ AAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients

Regeneron teams up with Alnylam to develop new RNAi therapies

Apr. 8, 2019 7:28 AM ET|About: Alnylam Pharmaceutical... (ALNY)|By: Douglas W. House, SA News Editor

April 8, 2019 at 7:00 AM EDT Back REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 8, 2019 /PRNewswire/ -- Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases Regeneron to invest $800 million through upfront cash and equity investment in Alnylam, with up to additional $200 million in potential near-term milestones

Systemic Gene Transfer w/ AAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients

Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference

Mon April 8, 2019 8:30 AM|GlobeNewswire|About: SRPTGlobeNewswire

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (SRPT)

https://www.sarepta.com/our-pipeline

Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference April 8, 2019 at 8:30 AM EDT -Six additional poster presentations highlighting data from Sarepta’s RNA and gene therapy programs also accepted-- CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

developing and commercializing novel tetracyclines

Systemic Gene Transfer w/ AAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients

developing and commercializing novel tetracyclines

Mon April 8, 2019 7:00 AM|Business Wire|About: TTPH

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH) (NASDAQ:TTPH)

https://www.xerava.com/

XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.

TETRAPHASE PHARMACEUTICALS TO PRESENT DATA AT THE 29TH EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES April 08, 2019 PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 8, 2019-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)

erdafitinib

Afirma® Genomic Sequencing Classifier

developing and commercializing novel tetracyclines

Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.

Mon April 8, 2019 9:00 AM|GlobeNewswire|About: IMMU

MORRIS PLAINS, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), (NASDAQ: IMMU)

Chicago Ill., June 3, 2018 Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer Treatment with investigational compound erdafitinib demonstrated durable responses in patients with metastatic urothelial cancer with genetic alterations

Afirma® Genomic Sequencing Classifier

Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype

Mon April 8, 2019 7:30 AM|Business Wire|About: VCYT

RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT)

https://bmcsystbiol.biomedcentral.com/track/pdf/10.1186/s12918-019-0693-z

Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries April 08, 2019 07:30 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc

targeted drug delivery (TDD)

Afirma® Genomic Sequencing Classifier

New Study Finds Targeted Drug Delivery (TDD) is Associated with a Reduction in Health Care Utilization and Cost for Cancer Pain Patients

Mon April 8, 2019 8:00 AM|InPublic US|About: MDT

New Study Finds Targeted Drug Delivery (TDD) is Associated with a Reduction in Health Care Utilization and Cost for Cancer Pain Patients Savings Are Driven by Fewer Inpatient Visits, Shorter Inpatient Length of Stay, and Fewer Emergency Department Visits DUBLIN - April 8, 2019 - Medtronic plc (NYSE:MDT)

seeking biotech alpha April 2019 insight

luspatercept, an erythroid maturation agent

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets)

luspatercept, an erythroid maturation agent

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

Fri April 5, 2019 9:28 AM|Business Wire|About: CELG, XLRN

BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications

EMA marketing application for both indications planned for Q2:19

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN)

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications EMA marketing application for both indications planned for Q2:19 April 05, 2019 09:28 AM Eastern Daylight Time SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN)

Phase 3 REGENERATE

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets)

luspatercept, an erythroid maturation agent

Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019

Thu April 4, 2019 7:00 AM|GlobeNewswire|About: ICPTGlobeNewswire

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT)

Apr 4, 2019 Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019 PDF Version Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT)

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets)

Gilead files U.S. application HIV prevention claim for Descovy

Apr. 5, 2019 8:47 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor

https://www.descovy.com/

April 05, 2019 Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis - Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada® Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection - FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 5, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD)

HeartWare(TM) HVAD(TM) System as destination therapy

a gap in the diagnosis and treatment of osteoporosis in Europe

Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets)

DUBLIN and ORLANDO, Fla. - April 5, 2019 - Medtronic plc (MDT)

Medtronic HeartWare(TM) HVAD(TM) System Demonstrates Reduction in Total Strokes, Disabling Strokes and Stroke-Related Mortality with Blood Pressure Management

Fri April 5, 2019 10:00 AM|InPublic US|About: MDT

Medtronic HeartWare(TM) HVAD(TM) System Demonstrates Reduction in Total Strokes, Disabling Strokes and Stroke-Related Mortality with Blood Pressure Management ompany Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient Outcomes DUBLIN and ORLANDO, Fla. - April 5, 2019 - Medtronic plc (NYSE:MDT)

generic pharmaceuticals

a gap in the diagnosis and treatment of osteoporosis in Europe

PE firms eyeing Perrigo pharma business

Apr. 4, 2019 12:27 PM ET|About: Aclaris Therapeutics, ... (ACRS)|By: Douglas W. House, SA News Editor

Bloomberg = Apollo, CVC Are Vying for Perrigo's Pharmaceuticals Unit By Gillian Tan and Manuel Baigorri April 4, 2019, 11:27 AM EDT

a gap in the diagnosis and treatment of osteoporosis in Europe

Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe

Sun April 7, 2019 5:00 AM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (AMGN)

http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2393722

THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (AMGN) NEWS PROVIDED BY Amgen Apr 07, 2019, 05:00 ET Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe Study Shows 55 Percent of Women Over 70 Years Old are at Risk of Fragility Fractures With 75 Percent of Them not Treated for Osteoporosis

seeking biotech alpha April 2019 insight

IBRANCE® (palbociclib

BRACAnalysis CDx® to ID germline BRCA mutations in men - metastatic castrate-resistant prostate canc

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

Thu April 4, 2019 2:57 PM|Business Wire|About: PFE

Approval of expanded indication based predominately on real-world data

NEW YORK--(BUSINESS WIRE)-- Pfizer (PFE)

https://www.businesswire.com/news/home/20190404005732/en/

https://www.ibrance.com/

U.S. FDA APPROVES IBRANCE® (PALBOCICLIB) FOR THE TREATMENT OF MEN WITH HR+, HER2- METASTATIC BREAST CANCER APPROVAL OF EXPANDED INDICATION BASED PREDOMINATELY ON REAL-WORLD DATA Thursday, April 4, 2019 - 2:57pm EDT Pfizer (NYSE:PFE)

BRACAnalysis CDx® to ID germline BRCA mutations in men - metastatic castrate-resistant prostate canc

Myriad expands partnership with AstraZeneca and Merck

Apr. 4, 2019 8:27 AM ET|About: Myriad Genetics, Inc. (MYGN)|By: Mamta Mayani, SA News Editor

https://www.lynparzahcp.com/recurrent-ovarian-cancer/parp-inhibitor-ovarian-cancer.html

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metastatic Castrate-Resistant Prostate Cancer SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN)

SELLAS Life Sciences' (SLS) galinpepimut-S (GPS) and Bristol-Myers Squibb's (BMY) Opdivo (nivolumab)

BRACAnalysis CDx® to ID germline BRCA mutations in men - metastatic castrate-resistant prostate canc

SELLAS Life Sciences' (SLS) galinpepimut-S (GPS) and Bristol-Myers Squibb's (BMY) Opdivo (nivolumab)

Leading cancer center to evaluate SELLAS' galinpepimut-S in mesothelioma

Apr. 4, 2019 10:07 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM) 04/04/19 nitiation of Phase 1 Clinical Trial in Relapsed or Refractory MPM Expected in the Second Quarter of 2019 Previous Combination Study of GPS and Nivolumab Given After Salvage Chemotherapy in Ovarian Cancer Patients Showed 1-year Progression-Free Survival Rate of 70% and Induction of WT1 Antigen-Specific Immunoglobulin G of 86% NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS)

MAVIRET™ (glecaprevir/pibrentasvir tablets)

authorized generic version of Merck's PROVENTIL (albuterol sulfate) HFA Inhalation Aerosol, 120mcg.

SELLAS Life Sciences' (SLS) galinpepimut-S (GPS) and Bristol-Myers Squibb's (BMY) Opdivo (nivolumab)

AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

Thu April 4, 2019 10:00 AM|Canada Newswire|About: ABBV

http://www.abbvie.ca/

AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™  Alberta, Saskatchewan and the Non-Insured Health Benefits (NIHB) Program list MAVIRET on their formularies  MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment*1  MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease MONTREAL, QC, April 4, 2019 – AbbVie (NYSE: ABBV)

VK2809 in patients w/ non-alcoholic fatty liver disease (NAFLD) & elevated low-density (LDL-C)

authorized generic version of Merck's PROVENTIL (albuterol sulfate) HFA Inhalation Aerosol, 120mcg.

Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019

Thu April 4, 2019 7:30 AM|PR Newswire|About: VKTXPR Newswire

SAN DIEGO, April 4, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX)

SAN DIEGO, April 4, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX) NEWS PROVIDED BY Viking Therapeutics, Inc. Apr 04, 2019, 07:30 ET Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019 Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm

authorized generic version of Merck's PROVENTIL (albuterol sulfate) HFA Inhalation Aerosol, 120mcg.

Endo to supply generic version of PROVENTIL in U.S.

Apr. 5, 2019 7:48 AM ET|About: Endo International plc (ENDP)|By: Mamta Mayani, SA News Editor

https://www.proventilhfa.com/pfha/index.xhtml

Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States APRIL 5, 2019 Download PDF DUBLIN, April 5, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP)

seeking biotech alpha is biotecMAX 生物技术最大 4/20/2021 the heart of biotech

seeking biotech alpha April 2019 insight

Novartis AG (NVS)

Thermo Fisher Scientific Inc. (TMO)

Novartis AG (NVS)

Biogen Inc. (BIIB)

Thermo Fisher Scientific Inc. (TMO)

Novartis AG (NVS)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

FARXIGA

Boston Scientific Corporation (BSX)

Trulicity® (dulaglutide)

Trulicity® (dulaglutide)

Boston Scientific Corporation (BSX)

Trulicity® (dulaglutide)

seeking biotech alpha April 2019 insight

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

SPINRAZA™(nusinersen)

Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, & combination pembrolizumab [KEYTRUDA®

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

LOTUS Edge™ Aortic Valve System

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

LOTUS Edge™ Aortic Valve System

Stryker Corporation (SYK)

SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor,

LOTUS Edge™ Aortic Valve System

seeking biotech alpha April 2019 insight

KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib)

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib)

Taltz® (ixekizumab)

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib)

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

VenaSeal(TM) Closure System in treating patients with chronic venous disease.

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

SKYRIZI™(risankizumab)

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Amgen Biotech Experience (ABE) program in Tampa, Florida

Amgen Biotech Experience (ABE) program in Tampa, Florida

Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1

Amgen Biotech Experience (ABE) program in Tampa, Florida

seeking biotech alpha April 2019 insight

guselkumab (Tremfya(R))

timing of treatment and serum creatinine (SCr) at treatment start

brolucizumab (RTH258) for patients with wet AMD

brolucizumab (RTH258) for patients with wet AMD

timing of treatment and serum creatinine (SCr) at treatment start

brolucizumab (RTH258) for patients with wet AMD

timing of treatment and serum creatinine (SCr) at treatment start

timing of treatment and serum creatinine (SCr) at treatment start

timing of treatment and serum creatinine (SCr) at treatment start

Wuxi Biologics (Cayman) In... (WXXWY)

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

timing of treatment and serum creatinine (SCr) at treatment start

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

Fast Track Designation for CTX001

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH)

seeking biotech alpha April 2019 insight

ZERBAXA® (ceftolozane and tazobactam)

FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for w/ BALVERSA™ (erdafitinib)